June 01, 2019
3 min watch
Save

VIDEO: New MIGS devices bring different advantages to glaucoma treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Thomas W. Samuelson, MD, discusses the strengths and weaknesses of the new MIGS devices on the U.S. market, including the iStent inject (Glaukos), Hydrus (Ivantis), Xen (Allergan) and Omni (Sight Sciences) devices.